Literature DB >> 25441837

Possible target for preventing fibrotic scar formation following acute myocardial infarction.

Bruno Cvjeticanin1, Maja Prutki2, Ivo Dumic-Cule3, Zoran Veir3, Lovorka Grgurevic4, Slobodan Vukicevic4.   

Abstract

Bone morphogenetic protein 1 (BMP1) was originally isolated from bone with other BMPs due to its affinity for heparin. While all other BMPs are members of the Transforming Growth Factor β (TGFβ) superfamily of growth factors, BMP1 is not an authentic member of the BMP protein family. Together with mammalian Tolloid Like protein 1 (mTLL-1) and mTLL-2, BMP1 comprise a small group of zinc- and calcium-dependent proteinases. Acute myocardial infarction (AMI) is the leading cause of death in developed countries which accounts for 13% of deaths worldwide. It was recently shown that inhibition of BMP1-3 reduces progression of fibrosis in chronic kidney disease and suggested that BMP1-3 is an important molecule for fibrogenesis. We hypothesize that inhibition of BMP1-3 represents future of therapeutic interventions in the heart tissue fibrosis following AMI. This novel approach aims to acquire the first candidate specific treatment for recuperating the heart function in patients with AMI.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25441837     DOI: 10.1016/j.mehy.2014.09.011

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  4 in total

1.  Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1.

Authors:  Lara S Kallander; David Washburn; Mark A Hilfiker; Hilary Schenck Eidam; Brian G Lawhorn; Joanne Prendergast; Ryan Fox; Sarah Dowdell; Sharada Manns; Tram Hoang; Steve Zhao; Guosen Ye; Marlys Hammond; Dennis A Holt; Theresa Roethke; Xuan Hong; Robert A Reid; Robert Gampe; Hong Zhang; Elsie Diaz; Alan R Rendina; Amy M Quinn; Bob Willette
Journal:  ACS Med Chem Lett       Date:  2018-07-02       Impact factor: 4.345

Review 2.  The expression of Smad signaling pathway in myocardium and potential therapeutic effects.

Authors:  Yuping Duan; Wei Zhu; Min Liu; Muhammad Ashraf; Meifeng Xu
Journal:  Histol Histopathol       Date:  2016-11-15       Impact factor: 2.303

3.  Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction.

Authors:  Slobodan Vukicevic; Andrea Colliva; Ivo Dumic-Cule; Serena Zacchigna; Vera Kufner; Valentina Martinelli; Silvia Moimas; Simone Vodret; Viktorija Rumenovic; Milan Milosevic; Boris Brkljacic; Diana Delic-Brkljacic; Ricardo Correa; Mauro Giacca; Manuel Maglione; Tatjana Bordukalo-Niksic
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 14.919

4.  Serum Levels of Bone Morphogenetic Proteins 2 and 4 in Patients with Acute Myocardial Infarction.

Authors:  Maria Kercheva; Anna M Gusakova; Tamara R Ryabova; Tatiana E Suslova; Julia Kzhyshkowska; Vyacheslav V Ryabov
Journal:  Cells       Date:  2020-09-27       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.